organization · Reporting owner
VERTEX PHARMACEUTICALS INC / MA
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | 10% owner | December 26, 2018 | December 28, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date December 26, 2018 · Filed December 28, 2018
Jointly reported with Vertex Pharmaceuticals (Europe) Ltd
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 5,380,940 |
Last balance in matching sequence
After 2018-12-27 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-12-26 · Purchase · Acquired 12,737 · Balance 5,353,479 F1: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. F2: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.69 and $25.00. Row 2 · 2018-12-27 · Purchase · Acquired 27,461 · Balance 5,380,940 F1: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. F3: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.85 and $25.00. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe.
F2: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.69 and $25.00.
F3: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.85 and $25.00.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Altus Pharmaceuticals Inc.
Report date July 31, 2006 · Filed August 02, 2006
Section 16 reporting ended · disclosed 2006-08-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2006-07-31 transaction · row 1
1 source rowRow 1 · 2006-07-31 · Sale · Disposed 817,749 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy CEO personally | 30,528 |
Reported balance
Holding disclosure · report date 2006-07-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 30,528 F1: Held by Joshua S. Boger, the President and Chief Executive Officer of Vertex Pharmaceuticals Incorporated. Vertex disclaims beneficial ownership of these shares |
| Redeemable Preferred StockSEC Table I · non-derivative | Direct | 450,000 |
Reported balance
Holding disclosure · report date 2006-07-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 450,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Held by Joshua S. Boger, the President and Chief Executive Officer of Vertex Pharmaceuticals Incorporated. Vertex disclaims beneficial ownership of these shares
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 27, 2018 Filed Dec 28, 2018 21:34 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | PurchaseCommon Shares | 27,461 | $24.95 | $685,116.25 |
DisclosureSEC source: 0001209191-18-064322 · doc4.xml · nonDerivative · entry 2 Vertex Pharmaceuticals (Europe) Ltd · CIK 0001761216 · 10% owner VERTEX PHARMACEUTICALS INC / MA · CIK 0000875320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,380,940 F1 · shares: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. F3 · price: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.85 and $25.00. F1 · balance_after: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. Read SEC document |
| December 26, 2018 Filed Dec 28, 2018 21:34 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | PurchaseCommon Shares | 12,737 | $24.89 | $317,077.43 |
DisclosureSEC source: 0001209191-18-064322 · doc4.xml · nonDerivative · entry 1 Vertex Pharmaceuticals (Europe) Ltd · CIK 0001761216 · 10% owner VERTEX PHARMACEUTICALS INC / MA · CIK 0000875320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,353,479 F1 · shares: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. F2 · price: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.69 and $25.00. F1 · balance_after: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. Read SEC document |
| December 24, 2018 Filed Dec 26, 2018 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | PurchaseCommon Shares | 53,655 | $24.97 | $1,339,695.60 |
DisclosureSEC source: 0001209191-18-064099 · doc4.xml · nonDerivative · entry 4 Vertex Pharmaceuticals (Europe) Ltd · CIK 0001761216 · 10% owner VERTEX PHARMACEUTICALS INC / MA · CIK 0000875320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,340,742 F1 · shares: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. F5 · price: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.82 and $25.00. F1 · balance_after: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. Read SEC document |
| December 24, 2018 Filed Dec 26, 2018 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | PurchaseCommon Shares | 11,742 | $23.18 | $272,139.64 |
DisclosureSEC source: 0001209191-18-064099 · doc4.xml · nonDerivative · entry 3 Vertex Pharmaceuticals (Europe) Ltd · CIK 0001761216 · 10% owner VERTEX PHARMACEUTICALS INC / MA · CIK 0000875320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,287,087 F1 · shares: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. F4 · price: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.02 and $23.25. F1 · balance_after: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. Read SEC document |
| December 24, 2018 Filed Dec 26, 2018 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | PurchaseCommon Shares | 2,603 | $22.91 | $59,646.96 |
DisclosureSEC source: 0001209191-18-064099 · doc4.xml · nonDerivative · entry 2 Vertex Pharmaceuticals (Europe) Ltd · CIK 0001761216 · 10% owner VERTEX PHARMACEUTICALS INC / MA · CIK 0000875320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,275,345 F1 · shares: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. F3 · price: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.69 and $23.00. F1 · balance_after: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | PurchaseCommon Shares | 22,742 | $22.58 | $513,477.97 |
DisclosureSEC source: 0001209191-18-064099 · doc4.xml · nonDerivative · entry 1 Vertex Pharmaceuticals (Europe) Ltd · CIK 0001761216 · 10% owner VERTEX PHARMACEUTICALS INC / MA · CIK 0000875320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,272,742 F1 · shares: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. F2 · price: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.46 and $22.70. F1 · balance_after: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe. Read SEC document |
| July 31, 2006 Filed Aug 2, 2006 16:43 UTC | Altus Pharmaceuticals Inc. ALTU · Entity 17384 | SaleCommon Stock | 817,749 | $14.28 | $11,677,455.72 |
DisclosureSEC source: 0000875320-06-000072 · edgar.xml · nonDerivative · entry 1 VERTEX PHARMACEUTICALS INC / MA · CIK 0000875320 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 31, 2006 Filed Feb 2, 2006 20:44 UTC | Altus Pharmaceuticals Inc. ALTU · Entity 17384 | ConversionSeries A Preferred Stock · Derivative | 381,596 | $5.73 Strike: $5.73 | $2,186,545.08 |
DisclosureSEC source: 0000875320-06-000007 · edgar.xml · derivative · entry 5 VERTEX PHARMACEUTICALS INC / MA · CIK 0000875320 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 381,596 shares Expires 2006-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents the conversion of shares of Series A Preferred Stock into shares of common stock in connection with the closing of the Issuer's initial public offering. Read SEC document |
| January 31, 2006 Filed Feb 2, 2006 20:44 UTC | Altus Pharmaceuticals Inc. ALTU · Entity 17384 | ConversionCommon Stock | 381,596 | $5.73 | $2,186,545.08 |
DisclosureSEC source: 0000875320-06-000007 · edgar.xml · nonDerivative · entry 3 VERTEX PHARMACEUTICALS INC / MA · CIK 0000875320 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents the conversion of shares of Series A Preferred Stock into shares of common stock in connection with the closing of the Issuer's initial public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.